RNS Number : 2339R
Fintel PLC
04 July 2022
 

04 July 2022

Fintel plc

(the "Company" or "Fintel")

 

Issue of shares

 

 

Fintel plc (AIM: FNTL) announces that it has today issued 242,763 ordinary shares of £0.01 each to satisfy certain share entitlements of members who have elected to exercise their options pursuant to the Members Share Option Plan (MSOP).

 

Application has been made for the 242,763 newly issued shares to be admitted to trading on AIM, and admission is expected to take place on 08 July 2022 ("Admission"). Following Admission, the Company's issued share capital will consist of 103,248,373 ordinary shares. There are no ordinary shares held in treasury. Therefore, following Admission, this figure of 103,248,373 should be used by shareholders as the denominator for the calculation by which they determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

For further information, please contact:

 

Fintel plc                                                                                                         via Instinctif Partners

Matt Timmins (Joint Chief Executive Officer)

Neil Stevens (Joint Chief Executive Officer)

David Thompson (Chief Financial Officer)

               

Zeus (Nominated Adviser and Joint Broker)                                        +44 (0) 20 3829 5000

Martin Green

Dan Bate

           

Investec Bank (Joint Broker)                                                                     +44 (0) 20 7597 5970

Bruce Garrow

David Anderson

Harry Hargreaves   

        

Instinctif Partners (Financial PR)                                                              +44 (0) 20 7866 7887

Mark Walter                                                                                                 fintel@instinctif.com

Tim Linacre 

 

Notes to Editors

 

Fintel is the UK's leading fintech and support services business, combining the largest provider of intermediary business support, SimplyBiz, and the leading research, ratings, and Fintech business, Defaqto.

Fintel provides technology, compliance and regulatory support to thousands of intermediary businesses, data and targeted distribution services to hundreds of product providers and empowers millions of consumers to make better informed financial decisions. We serve our customers through three core divisions:

The Intermediary Services division provides technology, compliance, and regulatory support to thousands of intermediary businesses through a comprehensive membership model. Members include directly authorised IFAs, Wealth Managers and Mortgage Brokers.

The Distribution Channels division delivers market Insight & analysis and targeted distribution strategies to financial institutions and product providers. Clients include major Life & Pension companies, Investment Houses, Banks and Building Societies.

The Fintech and Research division (Defaqto) provides market leading software, financial information and product research to product providers and intermediaries. Defaqto also provides product ratings (Star Ratings) on thousands of financial products. Financial products are expertly reviewed by the Defaqto research team and are compared and rated based on their underlying features & benefits. Defaqto ratings help consumers compare and buy financial products with confidence.

For more information about Fintel, please visit the website: www.wearefintel.com

                 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOELZLFBLDLFBBD